Literature DB >> 2487521

The digoxin-amiodarone interaction.

K Robinson1, A Johnston, S Walker, J P Mulrow, W J McKenna, D W Holt.   

Abstract

To assess the cause of the digoxin-amiodarone interaction, the systemic availability and renal excretion of digoxin were examined in 10 patients. Patients were studied before and after 1 week and 6 weeks of concurrent amiodarone therapy, and four were also studied after 4-8 months. Mean (+/- SD) peak plasma digoxin concentration rose from 1.55 +/- 0.6 microgram /1 prior to amiodarone therapy to 2.85 +/- 1.3 micrograms/1 after 1 week of combined therapy (p less than 0.01). Mean AUC also rose from 7.2 +/- 2.1 micrograms/1.h to 12.1 +/- 6.4 micrograms/1.h (p less than 0.01) during this period. Mean peak plasma digoxin concentration and AUC remained elevated after 6 weeks and, in the patients studied, at 4-8 months. Mean urinary digoxin clearance remained unchanged. Plasma amiodarone and desethylamiodarone concentrations were consistent with the prescribed doses. This study confirmed previous findings of raised plasma digoxin concentrations following the addition of amiodarone. It has also shown that this interaction is sustained for at least several months. The cause has not been fully elucidated but does not appear to be due to a change in the renal clearance of digoxin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2487521     DOI: 10.1007/bf01881526

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  10 in total

1.  Digoxin-desethylamiodarone interaction in the rat: comparison with the effects of amiodarone.

Authors:  N Venkatesh; B N Singh; L Al-Sarraf; R Kannan
Journal:  J Cardiovasc Pharmacol       Date:  1986 Mar-Apr       Impact factor: 3.105

2.  Influence of amiodarone on plasma and urine digoxin concentrations.

Authors:  P Douste-Blazy; J L Montastruc; B Bonnet; P Auriol; D Conte; P Bernadet
Journal:  Lancet       Date:  1984-04-21       Impact factor: 79.321

3.  Drug interactions with amiodarone.

Authors:  F I Marcus
Journal:  Am Heart J       Date:  1983-10       Impact factor: 4.749

4.  Amiodarone increases plasma digoxin concentrations.

Authors:  J O Moysey; N S Jaggarao; E N Grundy; D A Chamberlain
Journal:  Br Med J (Clin Res Ed)       Date:  1981-01-24

Review 5.  Measurement of the renal clearance of drugs.

Authors:  G T Tucker
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

6.  High-performance liquid chromatographic measurement of amiodarone and its desethyl metabolite: methodology and preliminary observations.

Authors:  G C Storey; D W Holt; P Holt; P V Curry
Journal:  Ther Drug Monit       Date:  1982       Impact factor: 3.681

7.  Digoxin toxicity associated with amiodarone therapy in children.

Authors:  G Koren; P S Hesslein; S M MacLeod
Journal:  J Pediatr       Date:  1984-03       Impact factor: 4.406

8.  Amiodarone-digoxin interaction: clinical significance, time course of development, potential pharmacokinetic mechanisms and therapeutic implications.

Authors:  K Nademanee; R Kannan; J Hendrickson; M Ookhtens; I Kay; B N Singh
Journal:  J Am Coll Cardiol       Date:  1984-07       Impact factor: 24.094

9.  Pitfalls in, and new methods for, the radioimmunoassay for digoxin in urine.

Authors:  M S O'Brien; J R Huston; R J Reid; T P Gibson
Journal:  Clin Chem       Date:  1985-01       Impact factor: 8.327

10.  Pharmacokinetic evaluation of the digoxin-amiodarone interaction.

Authors:  P E Fenster; N W White; C D Hanson
Journal:  J Am Coll Cardiol       Date:  1985-01       Impact factor: 24.094

  10 in total
  9 in total

1.  A Generic Model for Quantitative Prediction of Interactions Mediated by Efflux Transporters and Cytochromes: Application to P-Glycoprotein and Cytochrome 3A4.

Authors:  Michel Tod; S Goutelle; N Bleyzac; L Bourguignon
Journal:  Clin Pharmacokinet       Date:  2019-04       Impact factor: 6.447

2.  Are circulating metabolites important in drug-drug interactions?: Quantitative analysis of risk prediction and inhibitory potency.

Authors:  C K Yeung; Y Fujioka; H Hachad; R H Levy; N Isoherranen
Journal:  Clin Pharmacol Ther       Date:  2010-12-01       Impact factor: 6.875

3.  Application of receiver operating characteristic analysis to refine the prediction of potential digoxin drug interactions.

Authors:  Harma Ellens; Shibing Deng; Joann Coleman; Joe Bentz; Mitchell E Taub; Isabelle Ragueneau-Majlessi; Sophie P Chung; Krisztina Herédi-Szabó; Sibylle Neuhoff; Johan Palm; Praveen Balimane; Lei Zhang; Masoud Jamei; Imad Hanna; Michael O'Connor; Dallas Bednarczyk; Malin Forsgard; Xiaoyan Chu; Christoph Funk; Ailan Guo; Kathleen M Hillgren; Libin Li; Anne Y Pak; Elke S Perloff; Ganesh Rajaraman; Laurent Salphati; Jan-Shiang Taur; Dietmar Weitz; Heleen M Wortelboer; Cindy Q Xia; Guangqing Xiao; Tetsuo Yamagata; Caroline A Lee
Journal:  Drug Metab Dispos       Date:  2013-04-25       Impact factor: 3.922

Review 4.  Clinical Implications of P-Glycoprotein Modulation in Drug-Drug Interactions.

Authors:  Marie Lund; Tonny Studsgaard Petersen; Kim Peder Dalhoff
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

Review 5.  Clinical Relevance of Hepatic and Renal P-gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective.

Authors:  Kunal S Taskar; Xinning Yang; Sibylle Neuhoff; Mitesh Patel; Kenta Yoshida; Mary F Paine; Kim L R Brouwer; Xiaoyan Chu; Yuichi Sugiyama; Jack Cook; Joseph W Polli; Imad Hanna; Yurong Lai; Maciej Zamek-Gliszczynski
Journal:  Clin Pharmacol Ther       Date:  2022-06-22       Impact factor: 6.903

6.  Organic anion transporter oatp2-mediated interaction between digoxin and amiodarone in the rat liver.

Authors:  Takaaki Kodawara; Satohiro Masuda; Hiroko Wakasugi; Yuichi Uwai; Takahiro Futami; Hideyuki Saito; Takaaki Abe; Ken-ichi Inu
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

Review 7.  Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias.

Authors:  J Gill; R C Heel; A Fitton
Journal:  Drugs       Date:  1992-01       Impact factor: 9.546

Review 8.  Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa.

Authors:  Dolly A Parasrampuria; Kenneth E Truitt
Journal:  Clin Pharmacokinet       Date:  2016-06       Impact factor: 6.447

9.  Population pharmacokinetic analysis and dosage recommendations for digoxin in Japanese patients with atrial fibrillation and heart failure using real-world data.

Authors:  Toshinori Hirai; Hidefumi Kasai; Miyoko Naganuma; Nobuhisa Hagiwara; Tsuyoshi Shiga
Journal:  BMC Pharmacol Toxicol       Date:  2022-02-10       Impact factor: 2.483

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.